Ursula A. Matulonis, MD, on Future Focus With Mirvetuximab Soravtansine in Ovarian Cancer

Video

Ursula A. Matulonis, MD, speaks to potential future uses of mirvetuximab soravtansine in ovarian cancer.

Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer about future directions with mirvetuximab soravtansine (IMGN853) in ovarian cancer.

In addition to hoping that the drug will become a standard for the folate receptor α (FRα)–high platinum-resistant population following treatment with bevacizumab (Avastin), she explains that it may also have a role in platinum-sensitive and newly diagnosed advanced disease.

Transcript:

We’re hoping this drug is going to have a standard of care place for patients with [FRα-high] platinum-resistant, high-grade serous ovarian cancer [who] received prior bevacizumab through an accelerated approval. Certainly, this drug is combinable with other agents, such as bevacizumab and [platinum-based chemotherapy]. Right now, this trial is in more heavily pretreated patients with platinum-resistant ovarian cancer, but I definitely can see a role for it in platinum-sensitive disease, and also even moving it up front for patients with newly diagnosed advanced ovarian cancer.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Explore a rare case of vulvar epithelioid sarcoma, highlighting the role of SMARCB1 loss and the challenges of radiotherapy in treatment.

Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva

Fatimah M. Kaabi, MBBS;Chaker Zaidi, MD, PhD;Fatimah Abdullah Alessa, MBBS;Yasser Sorour, MD, PhD
October 27th 2025
Article

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.

Durvalumab Quadruplet Displays Nonsuperior OS in Advanced Ovarian Cancer

Kyle Doherty
October 19th 2025
Article

In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

Ashling Wahner
October 19th 2025
Article

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.